These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 15141331)

  • 1. The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness.
    Na-Bangchang K; Doua F; Konsil J; Hanpitakpong W; Kamanikom B; Kuzoe F
    Eur J Clin Pharmacol; 2004 Jun; 60(4):269-78. PubMed ID: 15141331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness.
    Jansson-Löfmark R; Na-Bangchang K; Björkman S; Doua F; Ashton M
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1299-307. PubMed ID: 25512417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness.
    Milord F; Loko L; Ethier L; Mpia B; Pépin J
    Trans R Soc Trop Med Hyg; 1993; 87(4):473-7. PubMed ID: 8249087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
    Milord F; Pépin J; Loko L; Ethier L; Mpia B
    Lancet; 1992 Sep; 340(8820):652-5. PubMed ID: 1355219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial.
    Van Nieuwenhove S; Schechter PJ; Declercq J; Boné G; Burke J; Sjoerdsma A
    Trans R Soc Trop Med Hyg; 1985; 79(5):692-8. PubMed ID: 3938090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of chronic trypanosomiasis on the bioavailability of alpha-difluoromethylornithine (DFMO) after oral administration: pharmacokinetics study on DFMO plasma levels in infected and noninfected mice using a high-performance liquid chromatography assay.
    Loiseau PM; Chauffert O; Czok M
    Parasitol Res; 1997; 83(4):386-9. PubMed ID: 9134564
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of human trypanosomiasis caused by Trypanosoma brucei gambiense using alpha-difluoromethylornithine. Results in 7 patients].
    Taelman H; Marcelis L; Sonnet J; Kazyumba G; Van den Enden E; Wery M; Schechter PJ
    Bull Soc Pathol Exot Filiales; 1988; 81(3 Pt 2):578-88. PubMed ID: 3143491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
    Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
    Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
    Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
    Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discrepancy in plasma melarsoprol concentrations between HPLC and bioassay methods in patients with T. gambiense sleeping sickness indicates that melarsoprol is metabolized.
    Bronner U; Brun R; Doua F; Ericsson O; Burri C; Keiser J; Miézan TW; Boa YF; Rombo L; Gustafsson LL
    Trop Med Int Health; 1998 Nov; 3(11):913-7. PubMed ID: 9855405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of sleeping disease caused by trypanosoma brucei gambiense with alpha-difluoromethylornithine (DFMO) in a rural hospital in Zaire].
    De Groof D; Bruneel H; Musumari TS; Ruppol JF
    Med Trop (Mars); 1992; 52(4):369-75. PubMed ID: 1494306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
    Priotto G; Kasparian S; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Karunakara U
    Clin Infect Dis; 2007 Dec; 45(11):1435-42. PubMed ID: 17990225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Côte d'Ivoire.
    Doua F; Boa FY; Schechter PJ; Miézan TW; Diai D; Sanon SR; De Raadt P; Haegele KD; Sjoerdsma A; Konian K
    Am J Trop Med Hyg; 1987 Nov; 37(3):525-33. PubMed ID: 3120607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on lipidomimetic derivatives of alpha-difluoromethylornithine (DFMO) to enhance the bioavailability in a Trypanosoma B. brucei murine trypanosomiasis model.
    Loiseau PM; Czok M; Chauffert O; Bourass J; Letourneux Y
    Parasite; 1998 Sep; 5(3):239-46. PubMed ID: 9772723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eflornithine. A new drug in the treatment of sleeping sickness.
    Van Bogaert I; Haemers A
    Pharm Weekbl Sci; 1989 Jun; 11(3):69-75. PubMed ID: 2505225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda.
    Kansiime F; Adibaku S; Wamboga C; Idi F; Kato CD; Yamuah L; Vaillant M; Kioy D; Olliaro P; Matovu E
    Parasit Vectors; 2018 Feb; 11(1):105. PubMed ID: 29471865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eflornithine for the treatment of human African trypanosomiasis.
    Burri C; Brun R
    Parasitol Res; 2003 Jun; 90 Supp 1():S49-52. PubMed ID: 12811548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The use of difluoromethylornithine in congenital trypanosomiasis due to Trypanosoma brucei-gambiense].
    Pepin J; Guern C; Milord F; Ethier L; Bokelo M; Schechter PJ
    Med Trop (Mars); 1989; 49(1):83-5. PubMed ID: 2498607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda.
    Matovu E; Enyaru JC; Legros D; Schmid C; Seebeck T; Kaminsky R
    Trop Med Int Health; 2001 May; 6(5):407-11. PubMed ID: 11348535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness.
    Khonde N; Pépin J; Mpia B
    Trans R Soc Trop Med Hyg; 1997; 91(2):212-3. PubMed ID: 9196773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.